FDA grants accelerated approval to zongertinib for expanded lung cancer indication
The agency cleared the kinase inhibitor for adults with unresectable or metastatic non-squamous non-small cell lung cancer.
The FDA announced accelerated approval of zongertinib, described as a kinase inhibitor, for an expanded indication. FDA granted accelerated approval to zongertinib, a kinase inhibitor, for an expanded indication for adults with unresectable or metastatic non-squamous non-small cell lung cancer.1
The FDA's posted notice does not include further detail beyond this indication statement.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.